Recursion Pharmaceuticals Form 144 Filed by Blake Borgeson
A Form 144 for Recursion Pharmaceuticals was filed by Blake Borgeson.
Related stories
Barclays Runs Sale Process for Exeter Finance’s Nonprime Auto Loans
Barclays is running a sale process for up to $1 billion of Exeter Finance’s nonprime auto loans.
M impact | EQUITY | Nov 03, 2026, 06:30 PM UTC
ZNB: trading halted on Nasdaq — volatility pause (1:23 PM ET)
Nasdaq halted trading in ZNB (volatility pause) at 1:23 PM ET.
L impact | EQUITY | Nov 03, 2026, 06:30 PM UTC
US session market picture: S&P 500 +0.53%, Nasdaq 100 +0.87%; EUR/USD +0.09%, WTI -0.43%, WBD leads volume
US session market picture. US index futures: S and P futures is up 0.53 percent, Nasdaq futures is up 0.87 percent, Dow futures is down 0.27 percent and Russell futures is up 0.69
M impact | EQUITY | Nov 03, 2026, 06:30 PM UTC
American Honda Sales Rise 8% in October
Honda Motor's American Honda unit reported an 8% sales rise in October.
L impact | EQUITY | Nov 03, 2026, 06:29 PM UTC
Campine Agrees to Acquire Minority Stake in Thailand’s Green Tech Antimony
M impact | EQUITY | Nov 03, 2026, 06:29 PM UTC
Beta Technologies Raises Annual Revenue Outlook; Shares Rise 15%
Beta Technologies raised its annual revenue outlook and cited a regulatory milestone allowing demonstration flights with prospective customers. Its stock rose 15% to $23.53.
M impact | EQUITY | Nov 03, 2026, 06:27 PM UTC